Answers are grounded in this paper and cite their sources.
(See the Major Article by Stabler et al on pages 727–37.) Rituximab (RTX) was the first monoclonal antibody against the CD20 protein expressed on the B-cell lineage, from the pre-B-cell stage to mature as well as malignant B cells [1]. RTX was approved for use in B-cell cancers in 1998, with life-transforming effects. It is currently also approved for the treatment of autoimmune diseases, mainly rheumatoid arthritis and anti-neutrophil cytoplasmic antibody associated vasculitides, and is used off-label for other autoimmune diseases. Because B-cell committed stem cells or plasma cells do not express CD20, hypogammaglobulinemia and consequent infection susceptibility were not initially expected [2]. We now know that prolonged and repeated RTX therapy can cause hypogammaglobulinemia and impaired specific-antibody response in a substantial proportion (upto 20–50% of the total) of recipients [3–5]. Furthermore, this RTX-induced hypogammaglobulinemia is commonly irreversible [6, 7]. Ultimately, RTX has been found to be associated with serious infective events (SIEs) and significant morbid effects, necessitating cessation of RTX treatment, and even death. Hence, it is important to understand the types of SIEs, their timing, and the factors that help predict them. The spectrum of SIEs previously encountered with RTX use across a range of indications is summarized in Table 1 (modified from reference [8]). As shown, the incidence and type of infection after RTX treatment varies according to patient age, indication, comorbid conditions, and other immunomodulation prescribed [2, 4, 7, 9–17] (Supplementary Table 1). The relative risk of infection seems to be highest among those with systemic vasculitides [7, 18], and long-term maintenance use of RTX has been associated with the development of neutropenia [9, 19]. Infections are mainly bacterial, especially affecting the sinopulmonary tract. Organisms include those typically seen in patients with primary antibody deficiency (eg, Pneumococcus or nontypable Haemophilus influenzae) [20], although infections with gram-negative organisms such as Pseudomonas or Klebsiella are also seen. Risk of Severe Infective Episodes Associated With Use of Rituximab Across Different Representative, Patient Groups Abbreviations: CI, confidence interval; DMARD, disease-modifying antirheumatic drug; HZV, herpes zoster virus; IGRT, immunoglobulin replacement therapy; NA, data not available; RA, rheumatoid arthritis, RR, relative risk; RTX, rituximab; SIEs, serious infections; SLE, systemic lupus erythematosus. Risk of Severe Infective Episodes Associated With Use of Rituximab Across Different Representative, Patient Groups Abbreviations: CI, confidence interval; DMARD, disease-modifying antirheumatic drug; HZV, herpes zoster virus; IGRT, immunoglobulin replacement therapy; NA, data not available; RA, rheumatoid arthritis, RR, relative risk; RTX, rituximab; SIEs, serious infections; SLE, systemic lupus erythematosus. There is a relatively small but significant proportion of infections caused by viruses, either de novo infections (West Nile virus or parvovirus B19) or infection reactivations (eg, cytomegalovirus, herpes zoster virus, herpes simplex virus, JC virus, and hepatitis B or C virus) [8]. Epstein-Barr virus reactivation is not seen, presumably owing to RTX-induced B-cell depletion. Fungal infections, including with Pneumocystis jirovecii, have been seen uncommonly and mainly when concomitant steroids are used [8]. Mycobacterial infections have been identified, but the numbers are too small to draw generalizations [8, 12]. Rtx leads to B-cell depletion. Rtx-dependent infections are mechanistically related to B-cell depletion, pan-hypogammaglobulinemia , impaired vaccine responses, B-cell/T-cell cross-talk and late-onset neutropenia [12]. Although the most common bacterial sinopulmonary infections are likely to be secondary to hypogammaglobulinemia, the broad range of infections seen probably reflects depleted B-cell–mediated antigen-presenting functions. Sinopulmonary infections with gram-negative organisms are probably secondary to established structural lung damage or gastroesophageal reflux, as in primary and secondary hypogammaglobulinemia [6, 21]. In this issue of The Clinical Infectious Diseases, Stabler et al [22] describe the incidence and nature of infections seen after RTX treatment in patients with autoimmune disease, primarily systemic lupus erythematosus, vasculitis, and autoimmune cytopenias. The incidence of SIEs in this large single-center French cohort (17.3/100 person-years at 1 year and 11.3/100 person-years at 2 years) is higher than in previous studies. The reason for this difference is unclear; it might reflect differences in RTX treatment indication or other factors, including the pattern of occurrence of pathogens and clinical practices in individual institutions (for instance, prophylactic antimicrobial use and vaccination status are not reported). The timing of SIEs (median time, 4.2 months) is similar to that seen other large studies [18, 23], although late-onset infections due to hypogammaglobulinemia or neutropenia may be underestimated, because follow-up ended 24 months after the start of RTX treatment. Pneumonia and bacteremia are the most common infectious presentations, and bacteria and fungi the most common pathogens. Although the range of bacterial infections reported by Stabler et al is similar to that in other published studies, the number of fungal infections is somewhat higher and the number of viral infections a somewhat lower than expected. Unfortunately, the true spectrum of pathogens remains unknown, given that a pathogen was not identified in more than a third of SIEs. It is also possible that viral reactivations were underestimated, because routine surveillance for these were not performed. The granularity of information provided by Stabler et al [22] also does not allow us to identify other contributory factors, such as the presence of underlying structural lung disease or nosocomial versus community SIE onset, which may have influenced pathogen type. Finally, RTX has been sporadically linked to the development of severe pulmonary complications, including alveolar hemorrhage, in patients with hematological cancers [24]. This presentation may mimic pneumonia. Thus, it would be relevant to determine whether any of the 14 “pneumonias” without an identified pathogen may have been the consequence of an immunological reaction. How can infections associated with RTX therapy be prevented? When RTX therapy causes hypogammaglobulinemia [4, 6, 7, 11, 18, 25–27], the rationale for immunoglobulin replacement therapy (IGRT), has been extrapolated from clinical experience in the context of primary hypogammaglobulinemia [28]. In the current study by Stabler et al [22], 10% of patients were treated with IGRT, but the study design did not allow the outcome of the therapy to be determined. Small studies indicate that IGRT in hypogammaglobulinemic patients decreases the incidence of SIEs [25, 27]. Criteria for initiating IGRT in patients with secondary hypogammaglobulinemia are not yet established because of the paucity of evidence. It has been proposed that the initiation of IGRT should be based on the degree of hypogammaglobulinemia, the nature of infections (serious, persistent, unusual, or recurrent), and demonstration of impaired antibody responses to polysaccharide antigens and the failure of antibiotic prophylaxis [29]. Although a scoring system to help select which patients should receive IGRT has been proposed [30], such a scheme has not been independently evaluated. In addition, several studies have shown that the incidence of bacterial infections can be reduced by pneumococcal and influenza vaccination [31, 32].The principle of screening for and treating latent hepatitis B virus infection is also supported by a strong consensus [8, 33]. Trimethoprim-sulfamethoxazole prophylaxis seems effective in preventing post-RTX SIE, in anti-neutrophil cytoplasmic antibody associated vasculitis [34], and in patients with secondary immunodeficiency due to myelomatosis [35]. Which RTX-treated patients require any or all of these preventive approaches? Although the findings reported by Stabler et al [22] suggest that lower CD4 lymphocyte counts at RTX initiation are independently associated with SIEs, given the variety of infectious risks, a multipronged prevention strategy based on each patient’s unique risks, including those present at baseline and those identified via monitoring during therapy, is likely to be most effective. In conclusion, despite a number of methodological factors that could induce bias, the large study from Stabler et al [22] helps raise awareness of the complexity of infectious risks in RTX-treated patients. This and previous publications emphasize the multiple potential risks for SIEs associated with RTX therapy. Long-term randomized, controlled clinical trials, aimed at defining monitoring strategies and personalized risk management for patients treated with RTX are needed; until then, we will have to depend on pharmacovigilance and extrapolation of preventive measures shown to be effective in other populations according to the specific infectious risk present. Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Potential conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Gkrania‐Klotsas et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: